APSR2026-123

 
Late-Breaking
Submitted
Poster Presentation
 
AP14-024
P43
 
Format: PPTX Only
https://storage.unitedwebnetwork.com/files/1285/1203531-46904-APSR-123_439978.pdf
Format: PDF Only
08. Lung Cancer
4

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

Jin Hong Vu * Tengku Ampuan Afzan Hospital Internal Medicine Department Kuantan Malaysia
Sin Nee Tan - Tengku Ampuan Afzan Hospital Respiratory Unit Kuantan Malaysia
Aishah Ibrahim - Tengku Ampuan Afzan Hospital Respiratory Unit Kuantan Malaysia
Soon Hin How - Tengku Ampuan Afzan Hospital Respiratory Unit Kuantan Malaysia
 
 
 
 
 
 
 
 
 
 
 
Presenting Author Details
Jin Hong
Vu
vujinhong@gmail.com
+60109199132
31-40
Malaysia
Case Report
Stevens-Johnson Syndrome Induced by Sotorasib in a Patient with KRAS G12C-Mutated Advanced NSCLC: A Case Report
Maximum 25 words
Abstract Content
 
 
 
 
Sotorasib is a first-in-class KRAS G12C inhibitor approved for the treatment of advanced non-small cell lung cancer (NSCLC) harboring KRAS G12C mutations. It is generally well tolerated, with commonly reported adverse effects including gastrointestinal disturbance and hepatotoxicity. Severe cutaneous adverse reactions such as Stevens-Johnson syndrome (SJS) was not reported, with no published case reports or formal literature reviews identified to date. Here, we report a case of SJS occurring in association with sotorasib therapy.
We report a case of a 58-year-old gentleman with metastatic lung adenocarcinoma harboring the KRAS G12C mutation was initiated on sotorasib (960 mg daily) following disease progression on platinum-based chemotherapy and immunotherapy. On day 34 of sotorasib therapy, the patient presented with acute onset of fever, oral ulcers, dysphagia and widespread maculopapular rash. Physical examination revealed erythematous rash involving approximately 5% of body surface area with mucosal and eye involvement. Sotorasib was promptly discontinued, and the diagnosis of SJS was made based on clinical presentation and dermatologist assessment. No alternative precipitating factors were identified. The patient was managed with systemic corticosteroids, cyclosporin, antibiotics, hydration and multidisciplinary approach, resulting in clinical improvement.
This case highlights a rare but life-threatening cutaneous reaction associated with sotorasib. Although targeted therapies are often perceived as having favorable safety profiles compared to cytotoxic chemotherapy, clinicians should remain vigilant for severe immune-mediated or idiosyncratic reactions. Early recognition and immediate drug cessation are critical to reduce morbidity and mortality. As the use of KRAS G12C inhibitors become more widely used, reporting of rare but serious adverse events such as SJS is essential to improve pharmacovigilance and guide clinical decision-making.
 
 
No
No
 
JPG or JPEG or PNG format ONLY
Sotorasib, Stevens-Johnson Syndrome, KRAS G12C
maximum 3 keywords and no abbreviations, separated by commas
 
265